⌬716
tinal polyposis using Apc ⌬716 knockout mice, a mouse mice with a novel COX-2 inhibitor reduced the polyp model of human FAP. Mutations in the human APC gene number more significantly than with sulindac, which have been demonstrated to play a role in FAP as well as inhibits both isoenzymes. These results provide direct sporadic cancers of the entire digestive tract (Boynton et genetic evidence that COX-2 plays a key role in tumorial., 1992; Horii et al., 1992; Powell et al., 1992) . We regenesis and indicate that COX-2-selective inhibitors cently constructed a knockout mouse strain that develcan be a novel class of therapeutic agents for coloops numerous polyps in the intestinal tract as early as rectal polyposis and cancer.
three weeks of age due to a truncation mutation in the Apc gene (Apc ⌬716 ) (Oshima et al., 1995a) . Due to the loss of the full-length wild-type Apc allele (Apc FL ) in Introduction the proliferative zone cells, i.e., loss of heterozygosity (LOH) by the second hit, these microadenomas origiThrough the investigation of the mechanism of action nated from single crypts by forming abnormal outpockof aspirin and other anti-inflammatory drugs, cyclooxyets into the inner (lacteal) side of the neighboring villi. genase (COX, PGHS, or PGH; prostaglandin-endoper- This mutant mouse strain provided a useful model sysoxide synthase, EC 1.14.99.1) has been established as tem for investigation of various carcinogens, and for the key enzyme responsible for prostanoid production evaluation of anticancer and chemopreventive agents. (Vane, 1971 (Vane, , 1994 . Conversion of arachidonic acid to
In fact, we demonstrated recently that heterocyclic prostaglandin G2 then to prostaglandin H2, is catalyzed amines that are generated in overcooked meat stimulate by two isozymes, COX-1 and COX-2. COX-1 was initially the growth of the intestinal polyps, whereas docosahexcharacterized, purified, and cloned from sheep seminal aenoic acid (DHA) reduces the number of polyps signifivesicles (Hemler and Lands, 1976; Miyamoto et al., 1976;  cantly when fed to the Apc ⌬716 mice (Oshima et al., 1995b, DeWitt and Smith, 1988) and is expressed constitutively 1996). Here we present the data that COX-2 plays a key in many but not all mammalian tissues (O'Neill and Fordrole in tumorigenesis and indicate that COX-2-selective Hutchinson, 1993). In contrast, COX-2 is induced in ininhibitors can be a novel class of therapeutic drugs for flammatory cells such as monocytes and macrophages polyposis and suitable chemopreventive agents for coupon stimulation by cytokines (Maier et al., 1990) Results control (statistical significance; P ϭ 0.0001, Figure 2A ). In the Apc ⌬716 (ϩ/Ϫ) Ptgs2(Ϫ/Ϫ) mice, polyp numbers were even lower; 93 Ϯ 98, i.e., ‫%41ف‬ of the control (P < Cyclooxygenase-2 (COX-2) Is Induced at Very Early Stages of Polyp Formation 0.0001, Figure 2A) . Moreover, the size of the polyps in the Apc ⌬716 (ϩ/Ϫ) Ptgs2(Ϫ/Ϫ) mice were significantly To examine the expression of COX-1 and COX-2 in the Apc ⌬716 mice, we performed immunoblot analyses of smaller. As shown in Figure 2B , no polyps were found larger than 2.0 mm in diameter, and most polyps were polyp proteins using specific antibodies against COX-1 and COX-2, respectively. As shown in Figure 1A , the <1.0 mm. Interestingly, not a single colonic polyp was found in the Apc ⌬716 (ϩ/Ϫ) Ptgs2(Ϫ/Ϫ) mice, whereas the normal intestinal epithelium, as well as the polyps of various sizes isolated from the small intestine, exApc ⌬716 (ϩ/Ϫ) Ptgs2(ϩ/Ϫ) and Apc ⌬716 (ϩ/Ϫ) Ptgs2(ϩ/ϩ) mice had 1.5 Ϯ 1.9 and 6.8 Ϯ 7.2 colonic polyps, respecpressed COX-1 protein. Essentially the same result was obtained with the normal colonic epithelium and the tively. These results indicate that expression of the COX-2 gene increases the polyp number and size in colonic polyps ( Figure 1C ). These results are consistent with earlier reports that COX-1 is a constitutive enzyme a gene dosage-dependent manner in the Apc ⌬716 (ϩ/Ϫ) mutant mice. This is the first direct genetic evidence (O'Neill and Ford-Hutchinson, 1993) . In contrast, the normal epithelium of neither the small intestine nor the colon that COX-2 plays a key role in polyp formation. contained any COX-2 protein detectable by this assay (lane 4 in Figures 1B and 1D , respectively). However, Novel COX-2-Selective Inhibitor MF Tricyclic Suppresses Polyp Formation in Apc ⌬716 Mice small intestinal polyps larger than 2 mm in diameter and all colonic polyps (1-6 mm) contained significant levels in a Dosage-Dependent Manner In order to determine whether we could mimic the Ptgs2 of COX-2 protein (lanes 6-9 in Figure 1B and lanes 5-9 in Figure 1D , respectively). Small intestinal polyps smaller mutation by administration of pharmaceutical agents, we tested the effects of a novel COX-2-selective inhibithan 2 mm did not show a detectable level of COX-2 (lane 5 in Figure 1B ). These results indicate that COX-2 tor MF tricyclic and a nonselective COX inhibitor, sulindac (Meade et al., 1993) . As shown in Table 1 , MF tricyis not present in the normal epithelia, but induced in the polyp tissues at a very early stage of polyp development.
clic inhibited human COX-2 but not human COX-1 stably expressed in CHO cells. In contrast, sulindac sulfide, the active form of sulindac is a potent inhibitor of both COX-2 Gene (Ptgs2) Knockout Mutation Introduced in Apc ⌬716 Mice Reduces human COX-1 and COX-2. The control Apc ⌬716 (ϩ/Ϫ) mice fed with the drug-free diet for eight weeks had 424 Ϯ the Polyp Number in a Gene Dosage-Dependent Manner 136 intestinal polyps (Figure 3) . When fed at 14 and 3.5 mg/kg/day, MF tricyclic reduced the polyp numbers to To determine the effect of the absence of COX-2 on Apc ⌬716 polyp formation, we introduced a knockout mu-161 Ϯ 60 (P < 0.0001) and 210 Ϯ 110 (P ϭ 0.0037), respectively. In contrast, the Apc ⌬716 (ϩ/Ϫ) mice fed with tation (Dinchuk et al., 1995) of the COX-2 gene (Ptgs2) into the Apc ⌬716 knockout mice by two successive 12 mg/kg/day sulindac contained 312 Ϯ 117 polyps (P ϭ 0.0982; statistically not significant). Thus, MF tricyclic crosses and generated double-mutant mice that carried Apc
reduced the polyp numbers by 62% and 50% of the control at 14 mg/kg and 3.5 mg/kg, respectively, commutations, respectively. The Apc ⌬716 (ϩ/Ϫ) Ptgs2(ϩ/ϩ) litter mates were used as positive controls, which depared with only a 26% reduction of polyp number by sulindac ( Figure 3 ). Colonic polyps in the control were veloped 652 Ϯ 198 (SD) polyps at the age of 10 weeks. When we examined the intestinal tracts of the 1.8 Ϯ 1.4 whereas those in Apc ⌬716 (ϩ/Ϫ) mice fed 14 mg/kg and 3.5 mg/kg MF tricyclic were 0.3 Ϯ 0.6 and Apc squares indicate males. The number and vertical bar to the right Size distribution of the intestinal polyps. Polyp sizes were classified of each sample group indicate the mean polyp number and SD, according to their diameters in millimeters. Sample, n ϭ 8 randomrespectively. The drug doses have been calculated from the concenized mice for each group.
trations of the drugs in the diet and the actual diet intakes.
in the mice fed 12 mg/kg sulindac were 0.9 Ϯ 0.9. At day was 0.45 Ϯ 0.24 (SD) g/ml. The mean plasma conthese drug concentrations, neither MF tricyclic nor sulincentration of the prodrug sulindac (fed 12 mg/kg/day) dac significantly affected body weights, food intake, or was 0.54 Ϯ 0.52 g/ml, whereas that of sulindac sulfide, the general condition of the Apc ⌬716 (ϩ/Ϫ) mice (data not the active form of sulindac, was 0.33 Ϯ 0.20 g/ml and shown). The plasma concentration of MF tricyclic in the that of the inactive metabolite sulindac sulfone was mice fed 3.5 mg/kg/day was below the detection limit 7.9 Ϯ 4.8 g/ml. of 0.1 g/ml, whereas that in the mice fed 14 mg/kg/ had similar heights to the villi ( Figure 4B ). Histologically, 11-20-96 14:32:02 060137$887 this difference is clearly shown in Figures 4C and 4D .
Inhibition of COX-2 Causes an Alteration in Polyp Morphology
bacterial ␤-galactosidase gene (lacZ). In this construct, the lacZ gene was placed under the control of the Ptgs2 The Ptgs2(Ϫ/Ϫ) polyps were much flatter (shorter) than those found in Ptgs2(ϩ/ϩ). Moreover, the Ptgs2(Ϫ/Ϫ) promoter and expressed as a fusion protein ( Figure 5 ). This knockout mutation was introduced into the Apc ⌬716 polyps were not covered with the normal intestinal epithelium as in the Ptgs2(ϩ/ϩ) polyps. Although to a lesser knockout mice [Apc
, and their polyps were analyzed. As seen in Figure 5C , the level extent, the same tendency was observed in polyps of the Apc ⌬716 (ϩ/Ϫ) Ptgs2(ϩ/Ϫ) mice as well as of the of the COX-2 protein was reduced to a half level in the (ϩ/Ϫ) polyp tissue, and a strong band immunoreactive Apc ⌬716 (ϩ/Ϫ) Ptgs2(ϩ/ϩ) mice treated with MF-tricyclic (data not shown).
with the LacZ antibodies was detected. When the polyp sections were examined immunohistochemically using specific antibodies against the bacterial enzyme, a In the Apc ⌬716 Polyps, COX-2 Is Expressed Essentially in the Interstitial Cells Rather marked expression of LacZ protein was detected in the polyps ( Figure 4E ). Interestingly, however, its expression Than in the Intestinal Epithelium To determine the site of COX-2 expression in the Apc ⌬716 was found essentially in the interstitial cells with large, ovoid and lightly stained nuclei, but not in the polyp polyps, we performed immunohistochemical analysis using the specific antibodies against COX-2. However, epithelium itself (see an adjoining section stained by H&E; Figure 4F ). The specificity of this assay was verified our antibodies were not strong enough to detect any signals in situ by immunohistochemistry (data not by two negative controls: an adjoining section stained with a non-immune rabbit IgG sample ( Figure 4G ) and shown). To overcome this technical problem, we constructed another strain of Ptgs2 knockout mouse in a section of an Apc
⌬716
(ϩ/Ϫ) polyp stained with the LacZ antibodies, which did not detect any signals ( Figure 4H ). which one of the Ptgs2 alleles was interrupted by a 11-20-96 14:32:02 060137$887 fact, accumulating evidence suggests that colorectal carcinoma tissues from both human patients and rodent models contain elevated levels of COX-2, the inducible isozyme of COX (Eberhart et al., 1994; Kargman et al., 1995; DuBois et al., 1996; Williams et al., 1996) . Here, we have demonstrated that COX-2 is induced in small polyps in the Apc ⌬716 (ϩ/Ϫ) intestines and colons ( Figure  1 ). These results indicate that induction of COX-2 is a very early event in the sequence of polyp formation to colon carcinogenesis and suggest that COX-2 plays a significant role in polyp development itself. Interestingly, however, the COX-2 expression in the polyp tissues was found essentially in the interstitial cells, rather than in the polyp epithelium itself ( Figure 4E ). Because the major prostanoid found in the colorectal cancer tissues appear to be prostaglandin E2 (PGE2; e.g., Rigas et al., 1993) , it is possible that the major end product of the PGH 2 generated by COX-2 induced in the interstitial cells are PGE 2 . It is also conceivable that the polyp epithelium itself generates some prostacyclin (PGI 2 ) because it has been demonstrated in culture that rat intestinal epithelium (RIE) cells stimulated by TPA or TGF␣ secrete PGI 2 (DuBois et al., 1994) . Tsujii and DuBois (1995) recently expressed the COX-2 gene in RIE cells at high levels. Such cells showed an increased tumorigenic potential that was reversed by sulindac. Moreover, these cells also have 3-fold increase in the duration of G1 that may relate to the resistance of these cells to undergo gene at codon 850 (Moser et al., 1990; Su et al., 1992) . DNA methyltransferase (Laird et al., 1995 ) are embryonic lethal (Li et al., 1992) . On the other hand, a major modifier gene affecting Apc MinBased on epidemiological data that showed a marked induced polyposis (Dietrich et al., 1993) has been proreduction in mortality from colorectal carcinoma in indiposed to encode secretory type II phospholipase A2 viduals taking NSAIDs, their efficacy in reducing the (gene symbol, Pla2s), and mouse strains that develop number and size of the colonic polyps in human FAP many polyps such as C57BL/6 and 129/Sv have greatly has been established recently in controlled trials (e.g., reduced levels of the enzyme (MacPhee et al., 1995) . It Giardiello et al., 1993) . Likewise, NSAIDs have been is interesting that Pla2s encodes one of several enzymes demonstrated to inhibit colorectal carcinogenesis in anithat catalyze generation of arachidonic acid, the ratemal models as well (e.g., Reddy et al., 1993; Boolbol et limiting precursor of prostaglandins and leukotrienes. al., 1996) . Although the molecular mechanism in which Because expression of Pla2s (e.g., in the AKR strain) NSAIDs reduce colorectal neoplasms remains unknown, reduces the polyp number rather than increases it, Pla2s may affect polyposis in an indirect manner such as a likely possibility is through their inhibition of COX. In scribed (Kargman et al., 1996) .
MF tricyclic. (ϩ/Ϫ) mice (Oshima et al., 1995a) and Acknowledgments Ptgs2(ϩ/Ϫ) mice (Dinchuk et al., 1995) have been described recently. Ptgs2 lacZ (ϩ/Ϫ) mice were constructed according to the strategy We thank the following individuals for help, suggestions, and discusshown in Figure 5 as described before (Oshima et al., 1995a Dinchuk et al., 1995; Oshima et al., 1995a) . Boolbol, S.K., Dannenberg, A.J., Chadburn, A., Martucci, C., Guo, Polyp Number Scoring X.J., Ramonetti, J.T., Abreu-Goris, M., Newmark, H.L., Lipkin, M.L., At the scheduled age, polyps were counted according to the method DeCosse, J.J., and Bertagnolli, M.M. (1996). Cyclooxygenase-2 described recently (Oshima et al., 1995a) (ϩ/Ϫ) mice were prepared as described recently (Oshima DeWitt, D.L. and Smith, W.L. (1988) . Primary structure of prostaglanet al., 1995a). Eight mice (4 females and 4 males, randomized from din G/H synthase from sheep vesicular gland determined from the 2-3 litters) were used for each group. After weaning at the end of complementary DNA sequence. Proc. Natl. Acad. Sci. USA 85, 1412-the third week, mice were fed ad libitum with the diet either with or 1416. without the drug for eight weeks till the end of the 11th week. Food Dietrich, W.F., Lander, E.S., Smith, J.S., Moser, A.R., Gould, D.A., intakes and body weights were monitored every week and the actual Luongo, C., Borenstein, N., and Dove, W. (1993) . Genetic identificadrug doses were calculated accordingly. Polyps were counted as tion of Mom-1, a major modifier locus affecting Min-induced intestidescribed above.
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